Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Peter A Bryden"'
Autor:
Jonathan AC Sterne, Pritesh N Bodalia, Peter A Bryden, Philippa A Davies, Jose A López-López, George N Okoli, Howard HZ Thom, Deborah M Caldwell, Sofia Dias, Diane Eaton, Julian PT Higgins, Will Hollingworth, Chris Salisbury, Jelena Savović, Reecha Sofat, Annya Stephens-Boal, Nicky J Welton, Aroon D Hingorani
Publikováno v:
Health Technology Assessment, Vol 21, Iss 9 (2017)
Background: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (L
Externí odkaz:
https://doaj.org/article/2145ae33ef2a41f69eb5c98fa9cf337a
Autor:
Howard H. Z. Thom, Will Hollingworth, Reecha Sofat, Zhenru Wang, Wei Fang, Pritesh N. Bodalia, Peter A. Bryden, Philippa A. Davies, Deborah M. Caldwell, Sofia Dias, Diane Eaton, Julian P. T. Higgins, Aroon D. Hingorani, Jose A. Lopez-Lopez, George N. Okoli, Alison Richards, Chris Salisbury, Jelena Savović, Annya Stephens-Boal, Jonathan A. C. Sterne, Nicky J. Welton
Publikováno v:
MDM Policy & Practice, Vol 4 (2019)
Objectives. Determine the optimal, licensed, first-line anticoagulant for prevention of ischemic stroke in patients with non-valvular atrial fibrillation (AF) in England and Wales from the UK National Health Service (NHS) perspective and estimate val
Externí odkaz:
https://doaj.org/article/6308f330e62448cdb06f8037a996fb26
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 45(10)
Simeprevir (SMV) is an oral, once-daily protease inhibitor for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. In phase II/III randomized controlled trials (RCT) conducted in Japan, SMV, in combination with peginterferon-α and